查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1733269

药物发现资讯学市场按应用、功能、最终用户和地区划分（2026 年至 2032 年）

Drug Discovery Informatics Market By Application (Drug Discovery, Drug Development), By Function (Sequence Analysis Platforms, Docking), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations), And Region For 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

药物发现资讯学市场评估（2026-2032）

由于药物发现日益复杂、药物开发时间缩短以及对个人化治疗的重视等因素，对药物发现资讯学的需求正在扩大。基因组学、蛋白质组学和人工智慧等技术的进步使研究人员能够收集和分析大量数据，从而增加了对组织和解释这些资讯的资讯学工具的需求。预计2024年市场规模将超过34.1亿美元，2032年将达到约75.7亿美元。

人们越来越重视针对特定疾病或患者群体的药物开发，这推动了对更先进的药物发现资讯系统的需求。对具有成本效益且高效的药物发现资讯学的需求不断增长，使得市场在 2026 年至 2032 年期间的复合年增长率达到 11.57%。

药物发现资讯学市场定义/概述

药物发现资讯学是应用计算工具和方法来改进药物发现和开发过程。这个跨学科领域使用数据管理、生物资讯学、化学资讯学和先进的分析工具来查询生物数据、化学特性和药物交互作用。它可以帮助研究人员找到有希望的候选药物，预测其功效和安全性，并优化其化学结构。应用包括虚拟化合物库的筛检、定量构效关係 (QSAR) 建模、生物标记识别和高通量筛检资料的合成。药物发现资讯学在现代药物研究中至关重要，因为它可以加速药物开发并增加成功的机会。

人工智慧 (AI)、机器学习和巨量资料分析的进步为药物发现资讯学带来了乐观的前景。预计这些技术将大大提高预测建模能力，使研究人员能够开发更有效、更有针对性的药物。体学数据（基因组学、蛋白质组学、代谢体学）的整合可以更全面地了解疾病机制，并有助于确定新的治疗目标。

随着产业走向精准医疗，药物发现资讯学有助于根据基因和分子特征为特定患者群体量身定制候选药物。云端运算的日益普及将使世界各地的研究人员更轻鬆地协作，从而有可能加快药物研发过程并改变新治疗方法的开发方式。

製药业研发支出的增加是否会推动药物发现资讯学市场的发展？

製药业研发支出的增加可能会推动药物发现资讯学市场的发展。 2019年，製药公司在研发方面投资了830亿美元，较2008年的480亿美元大幅成长，显示了它们对创新和发现新药的奉献精神。大量资金投入研发中，对先进资讯学解决方案的需求日益增长，这些解决方案可以简化和改进药物发现过程，使研究人员能够更有效地分析大量数据，识别有前景的候选药物，并最终加快新药上市的速度。

个人化医疗日益增长的需求正在推动药物发现资讯学市场的发展。个人化医疗的爆炸性成长，占 2018 年 FDA核准的新治疗方法的 25%（高于 2005 年的 5%），显示该产业致力于根据独特的患者情况调整治疗方法。这一趋势凸显了对改进资讯学工具的迫切需求，这些工具可以充分分析包括遗传、环境和生活方式方面的广泛数据。利用这些先进的资讯学解决方案，研发研究人员可以简化药物开发流程并改善治疗结果，从而推动药物发现资讯学市场的未来成长。

高成本会影响药物发现资讯学市场的成长吗？

高成本可能会影响药物发现资讯学市场的成长。规模较小的製药公司和新兴企业可能难以注入先进资讯工具、资料管理系统和技术人员所需的大量资金。这些高成本可能会限制获得最尖端科技的途径，并延迟突破性资讯解决方案的采用。许多公司面临的整体研发预算限制可能会导致药物发现资讯学支出的下降，从而阻碍市场成长，因为公司优先考虑关键支出而不是高阶数据分析能力。

缺乏标准化影响了药物发现资讯学市场的成长。如果没有全球认可的通讯协定和数据格式，跨多个平台整合和交换资讯就会变得困难，从而阻碍研究人员和机构之间的合作。当公司试图整合不同的资料集和流程时，这种分散会导致效率低下，最终减缓药物研发进程。缺乏标准会导致数据品质不一致，从而难以获得准确的见解并阻碍对药物发现资讯学解决方案的投资。

目录

第 1 章全球药物发现资讯学市场：简介

  • 市场介绍
  • 分析范围
  • 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球药物发现资讯学市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析
  • 法律规范

第五章全球药物发现资讯学市场（按应用）

  • 概述
  • 药物研发
  • 药物开发

6. 全球药物发现资讯学市场（按功能）

  • 概述
  • 序列分析平台
  • 分子建模
  • 对接
  • 序列和测试资料管理

第七章全球药物发现资讯学市场（按最终用户）

  • 概述
  • 製药和生物技术公司
  • CRO（委外研发机构）

8. 全球药物发现资讯学市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 世界其他地区

第九章全球药物发现资讯学市场的竞争格局

  • 概述
  • 企业市场占有率
  • 供应商格局
  • 主要发展策略

第十章 公司简介

  • Thermo Fisher Scientific, Inc.
  • PerkinElmer, Inc.
  • Certara, LP
  • Infosys Limited
  • Novo Informatics Pvt. Ltd.
  • Collaborative Drug Discovery Inc.
  • Selvita
  • Charles River Laboratories, Inc.
  • Jubilant Life Sciences Ltd.
  • IO Informatics, Inc.

第十一章 主要趋势

  • 产品发布/开发
  • 企业合併与收购（M&A）
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关分析
简介目录
Product Code: 33972

Drug Discovery Informatics Market Valuation - 2026-2032

The expanding demand for drug discovery informatics, including the increasing complexity of drug discovery, the desire to accelerate drug development timeframes, and the growing emphasis on customized treatment. Advances in technologies such as genomics, proteomics, and artificial intelligence are allowing researchers to collect and analyze massive amounts of data, increasing the demand for informatics tools to organize and interpret this information. The market size surpass USD 3.41 Billion valued in 2024 to reach a valuation of around USD 7.57 Billion by 2032.

The growing emphasis on creating targeted medicines for particular diseases and patient populations is driving demand for more advanced drug discovery informatics systems. The rising demand for cost-effective and efficient drug discovery informatics is enabling the market grow at a CAGR of 11.57% from 2026 to 2032.

Drug Discovery Informatics Market: Definition/ Overview

Drug Discovery Informatics is the application of computational tools and approaches to improve the process of drug discovery and development. This multidisciplinary discipline uses data management, bioinformatics, cheminformatics, and advanced analytical tools to examine biological data, chemical characteristics, and medication interactions. It helps researchers find prospective medication candidates, forecast their efficacy and safety, and optimize their chemical structures. Applications include virtual compound libraries screening, quantitative structure-activity relationship (QSAR) modeling, biomarker identification, and high-throughput screening data integration. Drug Discovery Informatics is essential in current pharmaceutical research since it accelerates drug development and increases the likelihood of success.

Drug Discovery Informatics is looking optimistic, thanks to advances in artificial intelligence (AI), machine learning, and big data analytics. These technologies are projected to greatly improve predictive modeling skills, enabling researchers to develop more effective and tailored medicines. The integration of omics data (genomics, proteomics, and metabolomics) will allow for a more comprehensive knowledge of disease mechanisms, leading to the identification of new therapeutic targets.

As the industry moves toward precision medicine, medication Discovery Informatics will help tailor medication candidates to specific patient populations based on genetic and molecular characteristics. The growing use of cloud computing will allow researchers around globally to collaborate more easily, speeding up the drug discovery process and, ultimately, changing how new treatments are developed.

Will the Increasing R&D Expenditure in the Pharmaceutical Industry Drive the Drug Discovery Informatics Market?

The increasing R&D spending in the pharmaceutical industry will propel the Drug Discovery Informatics market. Pharmaceutical companies invested USD 83 Billion in R&D in 2019, a significant increase from USD 48 Billion in 2008, demonstrating their dedication to innovation and the discovery of novel medicines. The significant financial resources invested in R&D create an increased demand for advanced informatics solutions that streamline and improve the drug discovery process, allowing researchers to analyze massive amounts of data more efficiently, identify promising drug candidates, and ultimately accelerate the timeline for bringing new drugs to market.

The rising need for personalized medicine will propel the drug discovery informatics market. The enormous increase in personalized medications, which accounted for 25% of all new FDA-approved therapies in 2018 (up from 5% in 2005), demonstrates the industry's dedication to adapting treatments to unique patient profiles. This trend highlights the critical need for improved informatics tools capable of properly analyzing a wide range of data, including genetic, environmental, and lifestyle aspects. Researchers can use these sophisticated informatics solutions to streamline drug development processes and improve treatment outcomes, driving future growth in the drug discovery informatics market.

Will the High Costs Impact the Growth of the Drug Discovery Informatics Market?

High costs will have an impact on the growth of the drug discovery informatics market. Smaller pharmaceutical companies and startups may find it difficult to make the considerable financial commitment required for advanced informatics tools, data management systems, and qualified personnel. These high costs may limit access to cutting-edge technologies, thereby stalling the adoption of breakthrough informatics solutions. The overall R&D budget constraints experienced by many organizations may result in reduced spending on drug discovery informatics, impeding market growth as companies prioritize vital expenditures over advanced data analytics capabilities.

The lack of standardization will have an impact on the growth of the drug discovery informatics market. Without globally acknowledged protocols and data formats, integrating and exchanging information across several platforms becomes difficult, thereby hindering collaboration among researchers and institutions. This fragmentation may result in inefficiencies as businesses attempt to integrate disparate data sets and processes, eventually slowing the drug discovery process. The lack of standards might result in variable data quality, making it difficult to obtain accurate insights and discouraging investment in drug discovery informatics solutions.

Category-Wise Acumens

What Factors Expand the Use of the Drug Discovery Informatics Market?

Sequencing & trial data management is currently the dominant segment in the drug discovery informatics market. The increasing availability of high-throughput sequencing technology will propel the sequencing & trial data management segment. These sophisticated technologies allow researchers to generate massive amounts of genetic data rapidly and inexpensively, greatly improving the ability to perform large-scale investigations and clinical trials. As the volume of sequencing data increases, there is a greater demand for comprehensive data management solutions that can efficiently process, analyze, and interpret this information.

The growth in genome data will propel the sequencing & trial data management segment. As genome sequencing technology evolves, the amount of data generated grows exponentially, necessitating the development of sophisticated data management solutions capable of efficiently storing, processing, and analyzing such huge amounts of information. This demand is driven by the need for researchers and clinicians to incorporate genetic data into their workflows, enabling customized medicine and more targeted therapeutic methods.

What Factors Boost the Use of the Drug Discovery Informatics Market?

Pharmaceutical and biotechnology companies are experiencing rapid growth segment in the drug discovery informatics market. Heavy investment in research and development (R&D) propels the Pharmaceutical & Biotechnology Companies Segment of the Drug Discovery Informatics Market, encouraging innovation and improving the drug discovery process. Pharmaceutical and biotech companies, which spent $83 billion on R&D in 2019, are increasingly looking for advanced informatics solutions to handle and analyze the massive amounts of data created during the discovery phase. This financing enables enterprises to capitalize on data-driven insights, increase candidate screening efficiency, and speed the development of new therapies.

The pharmaceutical & biotechnology companies segment of the drug discovery informatics market is likely to be driven by enhanced efficiency and cost reduction. As more companies use advanced informatics solutions, they can streamline their drug discovery processes, significantly reducing the time and resources required to bring new therapies to market. These efficiencies are accomplished by improving data management, predictive modeling, and automating procedures to decrease manual errors and redundancies. By cutting operational costs and increasing efficiency, pharmaceutical and biotechnology companies may devote more resources to innovation and competitive advantage, driving up demand for drug discovery informatics tools.

Country/Region-wise Acumens

Will the Advanced Research Institutions in the North American Region Propel the Drug Discovery Informatics Market?

North America leads the drug discovery informatics market. Advanced research institutions in North America will expand the drug discovery informatics market. These institutions are essential to encouraging innovation and growth, as indicated by the National Science Foundation's estimate that U.S. colleges and universities will invest USD 89.9 Billion in research and development in fiscal year 2021, with life sciences accounting for 56% of this expenditure. The National Institutes of Health (NIH) is further supporting this growth with a USD 39.2 Billion investment in medical research for fiscal year 2023, to improve drug discovery technologies and leverage artificial intelligence to potentially reduce early-stage drug development costs by 30-50% while shortening timelines.

The strong pharmaceutical and biotechnology industry in North America will power the drug discovery informatics market. In 2021, the U.S. biopharmaceutical industry would invest around USD 102.3 Billion in research and development, increasing need for advanced informatics tools to improve R&D efficiency and productivity. The FDA announced that 37 innovative medications were authorized in 2022, with many relying on sophisticated informatics and computational methodologies. By 2025, it is expected that more than half of new drug applications will use model-based research. The presence of over 6,441 biotech businesses actively embracing AI and machine learning, together with the NIH's funding of USD 1.5 Billion for biomedical informatics in 2023, demonstrates the robust investment and innovation that will drive the growth of the drug discovery informatics market.

Will the Rising Awareness of Drug Discovery Informatics Lead the Asian Pacific Region for the Drug Discovery Informatics Market?

The Asia-Pacific region is experiencing the fastest growth in the drug discovery informatics market. The growing awareness of drug discovery informatics is likely to propel the drug discovery informatics market in the Asia-Pacific region. Increased investments in drug discovery technology, particularly in nations such as India, which wants to have a USD 150 Billion biotech industry by 2025, and China, where AI-powered drug discovery companies have risen tenfold since 2018, highlight this trend. role in advancing the development of novel treatments to satisfy a variety of health needs.

The cost-effective labor in the Asia-Pacific region is a major driver of the drug discovery informatics market. The average salary for skilled biotechnology professionals in India is just $15,000, compared to $85,000 in the United States, making it financially appealing for pharmaceutical corporations to set up R&D units there. Since 2020, the number of bioinformatics specialists in the region has increased by 35%, with more growth expected. Outsourcing drug development efforts to Asia-Pacific can lower R&D costs by 25-45%, prompting more than 60% of global pharmaceutical corporations to build operations in the region by 2025. The combination of low-cost skilled labor and an expanding talent pool puts Asia-Pacific as a major participant in drug discovery informatics.

Competitive Landscape

The drug discovery informatics market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the drug discovery informatics market include:

  • Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery, Inc., Selvita, Charles River Laboratories, Inc., Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, Dassault Systemes.

Latest Developments

  • In April 2024, Sapio Sciences, the science-aware lab informatics platform, now supports multimodal registration. It combines small-molecule, large-molecule, and multimodal discovery methods, including entity registration, into a single platform.
  • In February 2023, Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (Al)-driven drug discovery business, revealed that it has received the FDA Orphan Drug Designation for its AI-discovered and designed medication for idiopathic pulmonary fibrosis.

Drug Discovery Informatics Market, By Category

  • Application
  • Drug Discovery
  • Drug Development
  • Function
  • Sequence Analysis Platforms
  • Molecular Modelling
  • Docking
  • Sequencing & Trial Data Management
  • End-User
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DRUG DISCOVERY INFORMATICS MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL DRUG DISCOVERY INFORMATICS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis
  • 4.5 Regulatory Framework

5 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY APPLICATION

  • 5.1 Overview
  • 5.2 Drug Discovery
  • 5.3 Drug Development

6 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY FUNCTION

  • 6.1 Overview
  • 6.2 Sequence Analysis Platforms
  • 6.3 Molecular Modelling
  • 6.4 Docking
  • 6.5 Sequencing & Trial Data Management

7 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Pharmaceutical & Biotechnology Companies
  • 7.3 Contract Research Organizations

8 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
  • 8.6 Rest of the World

9 GLOBAL DRUG DISCOVERY INFORMATICS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Share
  • 9.3 Vendor Landscape
  • 9.4 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Thermo Fisher Scientific, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 PerkinElmer, Inc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Certara, L.P.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Infosys Limited
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Novo Informatics Pvt. Ltd.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Collaborative Drug Discovery Inc.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Selvita
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Charles River Laboratories, Inc.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Jubilant Life Sciences Ltd.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 IO Informatics, Inc.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 APPENDIX

  • 12.1 Related Research